8. Over 70.000 patient data sets identified

To ensure that people trust technology, responsible privacy and security guidelines must be developed. HARMONY takes great care to follow ethical principles for biomedical research to ensure that no mistakes are made. One example is personal data security. Moreover, we must ascertain the quality of the data and their analysis, as only sound science is ethically justifiable.

Databarometer

The HARMONY Big Data Platform has identified clinical data from over 70,000 European patients. This will enable HARMONY Research Project Teams to characterize the molecular landscape of the key blood cancers, understand their pathophysiology, and identify novel drug targets. In addition, it will allow to reliably predict disease course and drug response for subgroups of patients. Ultimately, this should result in tools to rapidly select the most promising treatment strategy for a particular patient. In parallel, we are developing core outcome sets for blood cancers and organizing multi-stakeholder activities.

Receive the latest news. Click here to subscribe!

Public-private partnership for Big Data in Hematology

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).